Which adults with multiple myeloma is teclistamab (Tecvayli) indicated to treat as monotherapy?

Tecvayli (teclistamab) is indicated as monotherapy for adults with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-CD38 antibody, and whose disease progressed on the last therapy.